Considering the resistance of her arthritis to anti-TNF therapy, the potential pathogenic mechanism behind the disease and the existing clinical indication for JAK1/2 inhibitor for arthritis, the patient was switched to baricitinib, with a good clinical response. Here, JAK1 is linked to arthritic joint disease.